Bristol Myers Squibb Acquires Radiopharma Company RayzeBio
Bristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreBristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read moreStressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study
Read moreSwiss pharma giant Roche has entered an agreement to purchase Telavant Holdings, a Roivant company, owned by Roivant Sciences Ltd.
Read moreGSK plc has unveiled entering into a strategic collaboration with Chongqing Zhifei Biological Products, Ltd. (Zhifei), marking a pivotal move
Read moreElly Lilly announced plans to acquire POINT Biopharma, with the strategic move set to boost Lilly’s oncology capabilities with next-generation
Read moreOrano Med, a clinical-stage biotechnology company that develops the next generation of targeted therapies against cancer using the unique properties
Read more